#4

FORM PTO-1449 (Modified)	Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: DALE B. SCHENK et al.	
	Filing Date: May 26, 2000	Group: ~~1641~~ 1647

Reference Designation — **U.S. PATENT DOCUMENTS** — Page 1

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
___ AA	5,958,883	9/28/99	Snow			
___ AB	5,955,317	9/21/99	Suzuki et al.			
___ AC	5,955,079	9/21/99	Mond et al.			
___ AD	5,877,399	3/2/99	Hsiao et al.			
___ AE	5,869,093	2/9/99	Weiner et al.			
___ AF	5,869,054	2/9/99	Weiner et al.			
___ AG	5,854,204	12/29/98	Findeis et al.			
___ AH	5,851,996	12/22/98	Kline			
___ AI	5,849,298	12/15/98	Weiner et al.			
___ AJ	5,837,473	11/17/98	Maggio et al.			
___ AK	5,786,180	7/28/98	Konig et al.			
___ AL	5,753,624	5/19/98	McMichael et al.			
___ AM	5,750,349	5/12/98	Suzuki et al.			
___ AN	5,733,547	3/31/98	Weiner et al.			
___ AO	5,688,651	11/18/97	Solomon			
___ AP	5,679,348	10/21/97	Nesburn et al.			
___ AQ	5,645,820	7/8/97	Hafler et al.			
___ AR	5,641,474	6/24/97	Hafler et al.			
___ AS	5,641,473	6/24/97	Hafler et al.			
___ AT	5,612,486	3/18/97	McConlogue et al.			
___ AU	5,605,811	2/25/97	Seubert et al.			
___ AV	5,585,100	12/17/96	Mond et al.			
___ AW	5,571,500	11/5/96	Hafler et al.			
___ AX	5,571,499	11/5/96	Hafler et al.			
___ AY	5,434,170	7/18/95	Andrulis et al.			
___ AZ	5,387,742	2/7/95	Cordell			
___ BA	5,231,000	7/27/93	Majocha et al.			
___ BB	5,220,013	6/15/93	Ponte et al.			
___ BC	5,208,036	5/4/93	Eppstein et al.			
___ BD	5,192,753	3/9/93	McGeer et al.			
___ BE	5,057,540	10/15/91	Kensil et al.			
___ BF	4,666,829	5/19/85	Glenner er al.			

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
___ BG	WO 99/60024	11/25/99	PCT			

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Attorney Docket No.: 15270J-004760US Applicant: DALE B. SCHENK et al. Filing Date: May 26, 2000	Application No.: 09/580,018 Group: ~~1641~~ 1647
BH	WO 99/60021	11/25/99	PCT	
BI	WO 99/58564	11/18/99	PCT	
BJ	WO 99/27949	6/10/99	PCT	
BK	WO 99/27944	6/10/99	PCT	
BL	WO 99/27911	6/10/99	PCT	
BM	WO 99/06066	2/11/99	PCT	
BN	WO 98/44955	10/15/98	PCT	
BO	WO 98/07850	2/26/98	PCT	
BP	WO 97/17613	5/15/97	PCT	
BQ	WO 96/39176	12/12/96	PCT	
BR	WO 96/25435	8/22/96	PCT	
BS	WO 96/18900	6/20/96	PCT	
BT	WO 95/31996	11/30/95	PCT	
BU	WO 95/11311	4/27/95	PCT	
BV	WO 95/05853	3/2/95	PCT	
BW	WO 95/04151	2/9/95	PCT	
BX	WO 94/03615	2/17/94	PCT	
BY	WO 94/01772	1/20/94	PCT	
BZ	WO 93/21950	11/11/93	PCT	
CA	WO 93/16724	9/2/93	PCT	
CB	WO 93/15760	8/19/93	PCT	
CC	WO 93/14200	7/22/93	PCT	
CD	WO 93/02189	2/4/93	PCT	
CE	WO 92/13069	8/6/92	PCT	
CF	WO 92/06708	4/30/92	PCT	
CG	WO 92/06187	4/16/92	PCT	
CH	WO 91/16819	11/14/91	PCT	
CI	WO 91/19810	12/26/91	PCT	
CJ	WO 91/12816	9/5/91	PCT	
CK	WO 91/08760	6/27/91	PCT	
CL	WO 90/12871	11/1/90	PCT	
CM	WO 90/12870	11/1/90	PCT	
CN	WO 89/06242	7/13/89	PCT	
CO	WO 89/06689	7/27/89	PCT	
CP	WO 89/03687	5/5/89	PCT	
CQ	WO 88/10120	12/29/88	PCT	
CR	EP 506 785	3/15/00	Europe	
CS	EP 639 081	11/3/99	Europe	

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018	
			Applicant: DALE B. SCHENK et al.		
			Filing Date: May 26, 2000	Group: ~~1641~~ 1647	
CT	EP 561 087	8/4/99	Europe		
CU	EP 526 511	5/28/97	Europe		
CV	EP 911 036	4/28/99	Europe		
CW	EP 652 962	12/16/98	Europe		
CX	EP 868 918	10/7/98	Europe		
CY	EP 863 211	9/9/98	Europe		
CZ	EP 845 270	6/3/98	Europe		
DA	EP 594 607	8/27/97	Europe		
DB	EP 782 859	7/9/97	Europe		
DC	EP 440 619	1/24/96	Europe		
DD	EP 359 783	11/29/95	Europe		
DE	EP 683 234	11/22/95	Europe		
DF	EP 666 080	8/9/95	Europe		
DG	EP 451 700	10/16/91	Europe		
DH	EP 276 723	12/8/93	Europe		
DI	GB 2 335 192	9/15/99	United Kingdom		
DJ	GB 2 220 211	1/4/90	United Kingdom		

OPE NOV 03 2000 PATENT & TRADEMARK OFFICE

RECEIVED NOV 07 2000 TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DK	Andersen et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995).
DL	Associated Press, "Immune cells may promote Alzehimer's, a study finds," *The Boston Globe* (4/13/95).
DM	Bauer et al., "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991).
DN	Blass, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999).
DO	Bodmer et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," Biochem. Biophys. Res. Comm., 171(2):890-897 (1990).
DP	Borchelt et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins", Neuron, 19: 939-945 (1997).
DQ	Boris-Lawrie et al., "Recent advances in retrovirus vector technology", Cur. Opin. Genet Develop., 3: 102-109 (1993).
DR	Brice et al., "Absense of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993).
DS	Chao et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513.7 (1993).
DT	Duff et al., "Mouse model made", Nature, 373: 476-477 (1995)
DU	Elizan et al., "Antineurofilament antibodies in a postencephalitic and idiopathic parkinson's disease," J. Neurol. Sciences, 59:341-347 (1983).
DV	Felsenstein et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993).
DW	Finch et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5):809-815 (1996).

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018
	Applicant: DALE B. SCHENK et al.	
	Filing Date: May 26, 2000	Group: ~~1641~~ 1647

DX	Fisher et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779-1782 (1991).
DY	Flanders et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995).
DZ	Games et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein", Nature, 373(6514): 523-527 (1995).
EA	Gandy et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," TiPS, 13:108-113 (1992).
EB	Gaskin et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," J. Exp. Med., 177:1181-1186 (1993).
EC	Glenn et al., "Skin immunization made possible by cholera toxin", Nature, 391: 851 (1998).
ED	Glenner et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein", Biochemical and Biophysical Research Communications, 120(3): 885-890 (1994).
EE	Glenner et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein", Biochemical and Biophysical Research Communications, 122(3): 1131-1135 (1984).
EF	Goate et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991).
EG	Gozes et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS, 93:427-432 (1996).
EH	Gupta et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs", Vaccine, 15(12/13): 1341-1343 (1997).
EI	Haga et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Research, 601:88-94 (1993).
EJ	Hanes et al., "New advances in microsphere-based single-dose vaccines", Advanced Drug Delivery Reviews, 28: 97-119 (1997).
EK	Hardy, "Amyloid, the presenilins and Alzheimer's disease", TINS, 20(4): 154-159 (1997).
EL	Hardy, John, "New Insights into the Genetics of Alzheimer's Disease," Annals of Med., 28:255-258 (1996).
EM	Hsiao et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice", Science, 274: 99-102 (1996).
EN	Huberman et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994).
EO	Hyman et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995).
EP	Itagaki et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," J. Neuroimmunology, 24:173-182 (1989).
EQ	Jansen et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity", Immun. Rev., 62: 185-216 (1982).
ER	Kalaria, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992).
ES	Kawabata et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991).
ET	Lampert-Etchells et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993).
EU	Langer, "New Methods of Drug Delivery", Science, 249: 1527-1532 (1990).
EV	Lannfelt et al., "Alzheimer's disease: molecular genetics and transgenic animal models," Behavioural Brain Res., 57:207-213 (1993).

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018
	Applicant: DALE B. SCHENK et al.	
	Filing Date: May 26, 2000	Group: ~~1641~~ 1647

	EW	Lemere et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," Society for Neuroscience Abstracts, vol. 25, part I, Abstract 519.6, 29th Annual Meeting, 10/23-28/99.
	EX	Livingston et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection", J. Immunol., 159: 1383-1392 (1997).
	EY	Lopez et al., "Serum auto-antibodies in Alzheimer's disease," Acta. Neurol. Scand., 84:441-444 (1991).
	EZ	McGee et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility", J. Micro. Encap., 14(2): 197-210 (1997).
	FA	Meda et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995).
	FB	Miller et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991).
	FC	Nathanson et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic", Am. J. Epidemiol., 145(11): 959-969 (June 1, 1997).
	FD	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).
	FE	Paresce et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (September 1996).
	FF	Paul et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers", Eur. J. Immunol., 25: 3521-3524 (1995).
	FG	Prieels et al., "Synergistic adjuvants for vaccines", Chemical Abstracts, 120(8): pg. 652, column 1, abstract 86406t (1994).
	FH	Quon et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991).
	FI	Raso, V. A., "Immunotherapy of Alzheimer's Disease," Immunotherapy Weekly, Abstract (4/2/98).
	FJ	Rogers et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992).
	FK	Rossor et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:198-202 (1993).
	FL	Selkoe, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000).
	FM	Selkoe, Dennis J., "Amyloid Protein and Alzheimer's Disease……," Scientific American, pgs. 68-78 (11/91).
	FN	Selkoe, Dennis J., "In the Beginning…," Nature, 354:432-433 (1991).
	FO	Selkoe, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991).
	FP	Selkoe, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997).
	FQ	Selkoe, "Alzheimer's Disease: A Central Role for Amyloid", J. Neuropathol. Exp. Neurol., 53(5): 438-447 (1994).
	FR	Selkoe, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease", Trends in Neurosciences, 16(10): 403-409 (1993).
	FS	Seubert et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids", Nature, 359: 325-327 (1992).
	FT	Shiosaka, Sadao, "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992).
	FU	Smits et al., "Prion Protein and Scrapie Susceptibility", Vet. Quart., 19(3): 101-105 (1997).
	FV	Solomon et al., "Disaggregation of Alzheimer β-amyloid by site-directed mAb," PNAS, 94:4109-4112 (1997).
	FW	Solomon et al., "Monoclonal antibodies inhibit in *vitro* fibrillar aggregation of the Alzheimer β-amyloid peptide," PNAS, 93:452-455 (1996).
	~~FX~~	~~Solomon, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center.~~ improper format
	~~FY~~	~~Solomon, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, ramat-Aviv, Tel-Aviv, Israel.~~ improper format
	FZ	Stoute et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against *Plasmodium Falciparum* Malaria", N. Engl. J. Med., 336(2): 86-91 (1997).

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018
	Applicant: DALE B. SCHENK et al.	
	Filing Date: May 26, 2000	Group: ~~1641~~ 1647

☒	GA	Sturchler-Pierrat et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology", PNAS, 94: 13287-13292 (1997).
	GB	Tanaka et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998).
	GC	Trieb et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994).
	GD	Verbeek et al., "Accumulation of Intercellular Adheasion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994).
	GE	Walker et al., "Labeling of Cerebral Amyloid *In Vivo* with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994).
	GF	Wengenack et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Biotech., 18:868-824 (2000).
	GG	Weiner et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).
	GH	Weissmann et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease", Curr. Opin. Neurobiol., 7: 695-700 (1997).
☒	GI	Wood et al., "Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease", PNAS, 94: 1550-1555 (1997).
	~~GJ~~	~~Human Immunology & Cancer Program brochure, from The University of Tenessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee,~~ improper format

EXAMINER [signature] DATE CONSIDERED 12-5-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#6

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270J-004760US	Application No.: 09/580,018
	Applicant: Schenk et al.	
	Filing Date: May 26, 2000	Group: ~~1641~~ 1647

Reference Designation — **U.S. PATENT DOCUMENTS** — Page 1

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
AA	EP 613 007	8/31/94	Europe			
AB	WO 95/11994	5/4/95	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Schenk et al., "Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-177 (1999).
AD	Van Gool et al., "Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994).

EXAMINER _____ DATE CONSIDERED 12-5-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

#11

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

	Complete if Known
Application Number	09/580,018
Filing Date	05/26/00
First Named Inventor	Dale B. Schenk
Group Art Unit	~~1641~~ 1647
Examiner Name	~~Unassigned~~ NICHOLS
Attorney Docket Number	15270J-004760US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	196	6,150,091		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	207	5,780,587		Potter	07-14-1998	
	197	5,744,368		Goldgaber et al.	04-28-1998	
	211	5,736,142		Sette et al.	04-07-1998	
	175	5,441,870		Seubert, et al.	08-15-1995	
	181	5,270,165		Van Nostrand et al.	12-14-1993	
	32	5,187,153		Cordell et al.	02-16-93	
	198	5,004,697		Pardridge	04-0201991	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	187	EP	783 104	A1		07-09-1997		
	199	PCT	00/77178	A1		12-21-2000		
	188	PCT	00/43049	A1		07-27-2000		
	203	PCT	99/00150	A2		01-07-1999		
	202	PCT	97/21728	A1		06-19-1997		
	208	PCT	96/28471	A1		09-19-1996		
	200	PCT	95/12815	A1		05-11-1995		
	201	PCT	94/28412	A1		12-08-1994		
	205	PCT	93/04194	A1		03-04-1993		
	87	PCT	89/01343	A1		02-23-1989		

Examiner Signature		Date Considered	12-05-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3163030 v1

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/580,018
Filing Date	05/26/00
First Named Inventor	Dale B. Schenk
Group Art Unit	~~1641~~ 1647
Examiner Name	~~Unassigned~~ NICHOLS
Attorney Docket Number	15270J-004760US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," Eur. J. Immunol. 29:345-354 (1999).	
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheomer's Diseases," Soc. for Neuroscience Abstracts 18:764 (1992).	
	176	BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):916-919 (2000).	
	213	CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," Neuroscience Letters 125:223-226 (1991).	
	214	DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. USA, 10.1073/pnas.151261398 (2001).	
	210	FRIEDLAND et al., ""Development of an anti-A monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," Mol. Neurology, 9:107-113 (1994).	
	215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with $A\beta_{1-42}$," Annals of the New York Academy of Science 920:274-84 (2000).	
	190	GRAVINA et al., "Amyloid β Protein (Aβ) in Alzheimer's Disease," J. Biol. Chem., 270(13):7013-7016 (1995).	
	193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," Biochimica Biophysica Acta, 1158:120-128 (1993).	
	177	HELMUTH, L., "Further Progress on a β-Amyloid Vaccine," Science, 289:375 (2000).	
	192	IWATSUBO et al., "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," Neuron, 13:45-53 (1994).	
	216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," Am. J. of Pathology 138:373-378 (1991).	
	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," Biotechnol. Appl. Biochem., 23:227-230 (1996).	
	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the βA4 Peptide," Annals of NY Acad. Sci., 777:344-355 (1996).	
	218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992).	

Examiner Signature		Date Considered	12-05-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JAN 08 2002

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	09/580,018
Filing Date	05/26/00
First Named Inventor	Dale B. Schenk
Group Art Unit	~~1641~~ 1647
Examiner Name	~~Unassigned~~ NICHOLS
Attorney Docket Number	15270J-004760US

	217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA, 82:4245-4249 (1985).	☐
	206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992).	☐
	191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994).	☐
	~~144~~	~~RASO, V.A., Grant application # 1 R43 AGI 5748-01, (publication date unknown).~~ improper format	☐
	209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	☐
	189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J. Biol. Chem., 268(33):25239-25243 (1993).	☐
	194	SAIDO et al., "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," J. Biol. Chem., 269(21):15253-15257 (1994).	☐
	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," J. Med. Chem., 38(21):4141-4154 (1995).	☐
	182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation," Int. J. Exp. Clin. Invest., 3:130-133 (1996).	☐
	184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," Biochem. Mol. Biol. Int., 43(3):601-611 (1997).	☐
	185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," Adv. Mol. Cell Biology, 15A:33-45 (1996).	☐
	~~186~~	~~SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).~~ improper format	☐
	179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," J. Neurochemistry, 66:259-265 (1996).	☐
	180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," J. Food Drug Analysis, 6(2):465-476 (1998).	☐
	219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," Proc. Natl. Acad. Sci. USA, 82:8729-8732 (1985).	☐

Examiner Signature		Date Considered	12-05-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#18

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sheron Turner~~ Nichols
Attorney Docket Number	15270J-004760US

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.[1]	Document Number Number Kind Code[2] (*If known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DN	326	2002/0136718 A1	09-26-2002	Raso	
	325	2001/0102261 A1	08-01-2002	Raso	
	306	6,417,178 B1	07-09-2002	Klunk et al.	
	267	6,294,171 B2	09-25-2001	McMichael	
	234	6,284,221 B1	09-04-2001	Schenk, et al.	
	300	2001/0018053 A1	08-30-2001	McMichael	
	230	6,262,335 B1	07-17-2001	Hsiao et al.	
	305	09/724,842	11-28-2000	Chalifour et al.	
	231	6,114,133	09-05-2000	Seubert et al.	
	221	5,989,566	11-23-1999	Cobb et al.	
	283	09/441,140	11-16-1999	Solomon et al.	
	321	5,837,672	11-17-1998	Schenk et al.	
	320	5,593,846	01-14-1997	Schenk et al.	
	284	5,231,170	07-27-1993	Averback	
	~~242~~	~~60/168,594~~	~~N/A~~	~~Chalifour et al.~~	
	~~282~~	~~60/169,687~~	~~N/A~~	~~Chain~~	
	~~295~~	~~60/184,601~~	~~N/A~~	~~Holtzman et al.~~	
	~~296~~	~~60/254,465~~	~~N/A~~	~~Holtzman et al.~~	
	~~297~~	~~60/254,498~~	~~N/A~~	~~Holtzman et al.~~	
DN	~~299~~	~~60/186,295~~	~~N/A~~	~~Rasmussen et al.~~	

CONSIDERED-DO NOT GRANT.

Examiner Signature		Date Considered	4/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon Turner NICHOLS
Attorney Docket Number	15270J-004760US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
CW	294	WO	01/62801	A2	08-30-2001			
	301	WO	01/62284	A2	03-01-2000			
	298	WO	01/42306	A2	06-14-2001			
	243	WO	01/39796	A2	06-07-2001			
	322	WO	00/72880	A2, A3	12-07-2000			
	323	WO	00/72878	A2, A3	12-07-2000			
	324	WO	00/72870	A1	12-07-2000			
	240	WO	00/43039	A1	07-27-2000			
	331	WO	99/06545	A2	11-02-1999			
CW	227	WO	95/11008	A2	04-27-1995			

Examiner Signature		Date Considered	4/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

PTO/SB/08B (10-01)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon Turner
Attorney Docket Number	15270J-004760US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" J. Mol.Biol., 225(4): 1075-1093 (1992).	
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	
	327	CAMERON, "Recent Advances in Transgenic Technology," Molecular Biotechnology, 7:253-265 (1997).	
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin. Neuropharm., 15:414A-414B (1992).	
	~~224~~	~~Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm, last updated May 16, 2002.~~	
	266	CHAPMAN, PAUL F., "Model behavior," Nature, 408:915-916 (2000).	
	222	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)	

Examiner Signature		Date Considered	4/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3284657 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 18

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sheron Turner~~ DICHOSE
Attorney Docket Number	15270J-004760US

	307	CHEN, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408(6815):975-9 (2000).
	332	CHEN, et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice," Progress in Brain Research, Van Leeuwen et al. Eds, 117:327-337 (1998).
	302	CHUNG et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells," J. Biol. Chem., 274(45):32301-32308 (1999).
	291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000).
	333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," PNAS, 97(2):571-576 (2000)
	286	CORDELL, B., "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994).
	287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," Scand. J. Immunol., 38:177-182 (1993).
	293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63:2121-2131 (1998).

Examiner Signature		Date Considered	4/29/03

[1] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[2] Applicant's unique citation designation number (optional). [3] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sharon Turner~~ DLCHAS
Attorney Docket Number	15270J-004760US

	220	~~Dialog/Derwent, Abstract of WPI Acc No. 1997-054436/199706: Stable vaccine compsns. – comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.)~~
CTO	318	DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 57(5):801-5 (2001).
	288	DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-85 (2001).
	225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).
	226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)
	289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," Trends in Pharm. Sci., 22:2-3 (2001).
	328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" Alzheimer's and Parkinson's Diseases, Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).
	246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001).
CTO	245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 (1999).

Examiner Signature		Date Considered	4/29/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PA 3284657 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon Turner NICHOLS
Attorney Docket Number	15270J-004760US

CJO	247	FRENKEL et al., "Immunization against Alzheimer's β-amyloid-plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000).
	248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," J. of Neuroimmunology, 88:85-90 (1998).
	244	FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," J. of Neuroimmunology, 106:23-31 (2000).
	249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).
	251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," Biochem. Biophys. Res. Comm., 173:1292-1298 (1990).
	252	GEDDES, "N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," Neurobiology of Aging, 20:75-79 (1999).
	253	GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," Journal of Biological Chem., 273:29719-29726 (1998).
CJO	303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," Immunology, 93:149-153 (1998).

Examiner Signature		Date Considered	9/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3284657 v1

FTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sheron Turner~~ NICHOLS
Attorney Docket Number	15270J-004700US

	237	GORTNER, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949).
	254	GRUBECK-LOEBENSTEIN, et al., "Immunization with β-amyloid: could T-cell activation have a harmful effect?", TINS, 23:114 (2000).
	241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992).
	255	HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," Biochem. Biophys. Res. Comm., 211:1015-1022 (1995).
	229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993).
	236	HILBICH et al., :Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4," Eur. J. Biochem., 201:61-69 (1991).
	258	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody," Lab. Invest., 57:446-449 (1987).
	308	JANUS, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 408(6815):979-82 (2000).
	257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," Brain Research Protocols, 2:23-30 (1997).

Examiner Signature		Date Considered	4/29/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sharon Turner~~ NICHOLS
Attorney Docket Number	15270J-004760US

CRO	334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," Molecular Microbiology, 5(7):1755-1767 (1991).	
	258	KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:165-108 (1995).	
	259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," Curr. Ops. in Chemical Biology, 1:260-267 (1997).	
	260	LEMERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," Annals of the NY Acad. Sci., 920:328-331 (2000).	
	261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," Brain Research, 667:138-142 (1994).	
	263	MANN, et al., "Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $Aβ_{42(43)}$," Annals of Neurology, 40:149-156 (1996).	
	262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 196:105-108 (1995).	
CRO	335	MASLIAH et al., "β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," PNAS, 98(21):12245-12250 (2001).	

Examiner Signature		Date Considered	4/29/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PA 3284657 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 13

	Complete if Known
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sharon Turner~~ NICHOLS
Attorney Docket Number	15270J-004760US

CDO	309	MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 77(4):1081-132 (1997).	
	264	MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," J. of Neuroscience Res., 31:428-442 (1992).	
	238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," Virology, 243:158-166 (1998).	
	265	MENA, et al., "Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease," Acta Neuropathol., 89:50-56 (1995).	
	310	MERLUZZI, et al. Humanized antibodies as potential drugs for therapeutic use. Adv Clin Path. 4(2):77-85 (2000).	
	311	MORGAN, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):982-5 (2000).	
	233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989).	
	250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," Exp. Anim., 43:711-718 (1995).	
CDO	268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1995).	

Examiner Signature		Date Considered	4/29/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 13

Complete If Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sharon Turner~~ Nichols
Attorney Docket Number	15270J-004760US

CRO	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys;" J. of Med. Primatology, 27:244-252 (1998).
	235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," Biochim. Biophys. Acta, 104:480-486 (1965).
	329	NIEMANN, "Transgenic farm animals get off the ground;" Transgenic Research 7:73-75 (1998).
	280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," Biochem. Biophys. Res. Comm., 146:307-313 (1987).
	336	PERUTZ et al., "Amyloid fibers are water-filed nanotubes," PNAS, 99(8):5591-5595 (2002).
	232	PETERSON, et al., " Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," Laboratory Animal Science, 46(1):8-14 (1996).
CRO	269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," J. of Neuroscience Res., 46:709-719 (1996).
	~~304~~	~~RASO, V.A., Grant application #1 R43 AGI 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).~~
CRO	279	SAITO et al., "Vector-mediated delivery of ^{125}I-labeled β-amyloid peptide Ab$^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ^{1-40} vector complex," PNAS USA, 92:10227-10231 (1995).

Examiner Signature		Date Considered	4/29/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 2284557 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sharon Turner~~ NICHOLS
Attorney Docket Number	15270J-004760US

		278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti-β-protein monoclonal antibodies," Sapporo Med. J., 60:309-320 (1991).
		277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," Brain Res., 755:193-201 (1997).
		312	SCHENK, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 20(11):679-81 (2001).
		270	SCHENK, et al., "β-peptide immunization," Arch. Neurol., 57:934-936 (2000).
		313	SELKOE, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8(11):447-53 (1998).
		330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," Arterioscler Thromb Vasc Biol., 20:1425-1429 (2000).
		314	SIGURDSSON, et al. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 59(1):11-17 (2000).
		315	SINHA, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 920:206-8 (2000).
		337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," Trends in Biotech, 18(1):34-39 (2000).
		319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2(8):595-8 (2001).

Examiner Signature		Date Considered	4/29/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PA 3284657 v1

FTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sharon Turner~~ NICHOLS
Attorney Docket Number	15270J-004260US

CRO	316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med. 4(7):822-6 (1998).
	271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, :Antibody clears senile plaques," Nature, 40:116-117 (1999).
	338	STEIN and JOHNSON, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," The Journal of Neuroscience, 22(17):7380-7388 (September 1, 2002).
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β-peptide as modeled with N-terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-296 (1996).
	339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," PNAS, 92:4299-4303 (1995).
	273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," Curr. Op. in Chem. Biology, 4:377-382 (2000).
	276	TJERNBERG et al., "Arrest of β-amyloid fibril formation by a pentapeptide ligand," Journal of Biological Chemistry, 271:8545-8548 (1996).
CRO	317	VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. DNA Cell Biol. (11):713 21 (2001).

Examiner Signature		Date Considered	4/29/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 13

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	~~Sharon Turner~~ NICHOLS
Attorney Docket Number	15270J-004760US

GW	274	WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000).
	~~223~~	~~WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.)~~
GW	275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997).
↓	292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998).
GW	290	YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).

Examiner Signature		Date Considered	4/29/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PA 3284657 v1

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 1

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	15270J-004760US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CW	349	CHECK, "Battle of the Mind," Nature, 422:370-372 (March 2003).	
CW	350	Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report," Nature Medicine, 9(4):448-452 (April 2003).	

Examiner Signature		Date Considered	10/28/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 5

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Schenk, Dale B., et. al.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004760US

U.S. PATENT DOCUMENTS

Examiner	Cite No.[1]	Document Number Number Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CJN	360	2003/0073655 A1	04-17-2003	Chain	
	370	2003/0068325 A1	04-10-2003	Wang	
	378	2002/0197258 A1	12-26-2003	Ghanbari et al.	
	366	2002/0187157 A1	12-12-2002	Jensen et al.	
	377	2002/0168377 A1	11-14-2002	Schaetzl	
	340	2002/0162129 A1	10-31-2002	Lannfelt	
	395	2002/0160394 A1	10-**-2002	Wu	
	379	2002/0132268 A1	09-19-2002	Chang et al.	
	365	2002/0133001 A1	09-19-2002	Gefter et al.	
	362	2002/0094335 A1	07-18-2002	Chalifour et al.	
	376	2002/0086847	07-04-2002	Chain	
	342	2002/0009445 A1	01-24-2002	Du et al.	
	381	2001/0021769 A1	09-13-2001	Prusiner	
	345	2002/0077288 A1	06-21-2001	Frangione	
	346	5,935,927	08-10-1999	Vitek et al.	
	382	5,846,533	12-08-1998	Prusiner	
	353	5,824,322	10-20-1998	Balasubramanian	
	357	5,776,468 B1	07-07-1998	Hauser et al.	
	380	5,750,361	05-12-1998	Prusiner et al.	
	373	5,721,130	02-24-1998	Seubert et al.	
	356	5,622,701	04-22-1997	Berg	
CJN	358	5,583,112 B2	12-10-1996	Kensil et al.	

Examiner Signature		Date Considered	10/28/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] **Applicant's** unique citation designation number (**optional**). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 2 of 5

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Schenk, Dale B., et. al.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004760US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
CJN	343	EP	1 172 378	A1	01-16-2002			☐
	351	WO	02/34878	A2	05-02-2002			☐
	352	WO	02/34777	A1	05-02-2002			☐
	341	WO	02/03911	A2	04-07-2001			☐
	344	WO	01/90182	A2	11-29-2001			☐
	348	WO	01/77167	A2	10-18-2001			☐
CJN	383	WO	97/10505	A1	03-20-1997			☐
								☐
								☐
								☐
								☐

Examiner Signature		Date Considered	10/28/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 3 of 5

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Schenk, Dale B., et. al.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004760US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	391	AGUZZI et al., "Prion research: the next frontiers," Nature, 389:795-798 (1997).	
	393	AKIYAMA et al., "Inflammation and Alzheimer's disease," Neurobiology of Aging, 21:383-421 (2000).	
	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid β-Protein (Aβ) Deposits With Numerous Aβ-Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," Glia, 25:324-331 (1999).	
	349	CHECK, "Battle of the Mind," Nature, 422:370-372 (March 2003).	
	390	DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," Biochem. J., 320:53-570 (1996).	
	363	DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?" Trends in Molecular Medicine, 9(3):85-87 (2003).	
	386	FRATUTSCHY et al., "Effects of injected Alzheimer β-amyloid cores in rat brain," PNAS, 88:8362-8366 (1991).	
	364	FURLAN et al., "Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice," Brain, 126:285-291 (2003).	
	388	GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," Ann. Rev. Med., 46:57-65 (1995).	
	397	GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," PNAS, 96:3108-3113 (1999).	
V	374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," Alzheimer Disease and Associated Disorders, 9(1):47-51, Raven Press, Ltd., New York (1995).	
CJN	371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β-Amyloid Peptide (1-43) in Transfected 293 Cells," Biochemical and Biophysical Research Communications, 220:710-718 (1996).	

Examiner Signature		Date Considered	10/28/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 4 of 5

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Schenk, Dale B., et. al.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004760US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	347	JORBECK et al., "Artificial *Salmonella* Vaccines: *Salmonella typhimurium* O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," Infection and Immunity, May:497-502 (1981).	
	389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," J. Neurol., 249:1567-1582 (2002).	
	367	MONSONEGO et al., "Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," PNAS, 98(18):10273-10278 (2001).	
	359	MUNCH et al., "Potentional neurotoxic inflammatory response to Aβ vaccination in humans," (2002) J. Neural Transm., 109:1081-1087.	
	355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.	
	354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany.	
	350	NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report," Nature Medicine, 9(4):448-452 (April 2003).	
	398	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidiotic polyneuropathy, " J. Mol. Med., 7:703-707 (2001).	
	394	PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," PNAS, 90:10608-10612 (1993).	
✓	396	SIGURDSSON et al., "Anti-prion antibodies for prophylaxis following prion exposure in mice," Neurosciences Letters, 336:185-187 (2003).	
CJN	384	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," American Journal of Pathology, 161:13-17 (2002).	

Examiner Signature		Date Considered	10/28/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 5 of 5

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Schenk, Dale B., et. al.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004760US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	400	SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," Neurobiology of Aging, 23:1001-1008 (2002).	
	368	SIPE, "Amyloidosis," Annu. Rev. Biochem., 61:947-975 (1992).	
	369	SPOONER et al., "The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol," Vaccine, 21:290-297 (2002).	
	361	SU et al., "Intravascular infusions of soluble β-amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," Brain Research, 818:105-107 (1999).	
	392	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," Journal of Neuroscience Research, 71:286-290 (2003).	
	399	TAN et al., "Amyloidosis," Histopathology, 25:403-414 (1994).	
	375	TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-induced myopthy using end-specific antibodies for Aβ40 and Aβ42: immunohistochemical evidence for amyloid β protein," Neuroscience Letters, 2002:77-80 (1995).	
✓	387	WELDON et al., "Neurotoxicity of Aβ Peptide: Confocal Imaging of Cellular Changes Induced by β-Amyloid in Rat CNS *in Vivo*," Society for Neuroscicence Abstracts, 22(Part 1) (1996).	
CJN	385	WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," Biochemical Society Transactions, 30(4):-574-587 (2002).	

Examiner Signature		Date Considered	10/28/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 2

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Schenk, Dale B., et. al.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004760US

U.S. PATENT DOCUMENTS

Examiner	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	405	6,399,314 B1	06-04-2002	Krishnamurthy	
	401	6,284,533 B1	09-04-2001	Thomas	
	403	5,464,823	11-07-1995	Lehrer et al.	
	402	4,713,366	12-15-1987	Stevens	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
						☐
						☐
						☐
						☐
						☐
						☐
						☐
						☐
						☐
						☐
						☐

Examiner Signature		Date Considered	10/28/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 2 of 2

Complete if Known	
Application Number	09/580,018
Filing Date	May 26, 2000
First Named Inventor	Schenk, Dale B., et. al.
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	15270J-004760US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CJN	404	BENJAMINI and LESKOWITZ, from *IMMUNOLOGY A Short Course*, Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	
CJN	406	PAN et al., "Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide," Exp. Biol. Med., 227(8):609-615 (2002).	

Examiner Signature	CJN	Date Considered	10/28/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.